– USA, TX – Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Perry Nisen, M.D., Ph.D., to the Company’s Board of Directors. Dr. Nisen currently serves as the Chief Executive Officer and Donald Bren Chief Executive Chair of the Sanford Burnham Prebys Medical Discovery Institute, an independent biomedical research institute. Dr. Nisen oversees the organization’s strategic vision of becoming a leader in the growing field of translational medicine.
“We are delighted to welcome to our board an executive with Perry’s extensive pharmaceutical drug development and leadership experience,” said President and CEO Paul Lammers, M.D., M.Sc. “His proven ability to foster innovation and advance new products through the pipeline will be invaluable to our efforts to realize the full potential of our microRNA-based cancer therapies.”
“I look forward to working with fellow directors and the management team to advance Mirna’s pioneering approach to treating cancer,” said Dr. Nisen.
Before joining Sanford Burnham Prebys, Dr. Nisen served as Senior Vice President of Science and Innovation at GlaxoSmithKline (GSK), where he facilitated innovation and integration of R&D across GSK’s global organization and was integral to the discovery, development, and commercialization of a vast portfolio of drugs. Earlier in his career at GSK, he held various key positions, including interim Chief Medical Officer, Senior Vice President and Oncology Therapy Area Head, Senior Vice President of Cancer Research, and Senior Vice President of Clinical Pharmacology and Discovery Medicine. Previously, Dr. Nisen was the Divisional Vice President of Cancer Research and Oncology Development at Abbott Laboratories.
Formerly, Dr. Nisen was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. He holds a B.S. from Stanford University and M.D. and Ph.D. from the Albert Einstein College of Medicine.
About Mirna Therapeutics, Inc.
Mirna is a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna’s lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The Company was founded in 2007 and is located in Austin, Texas.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
